These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28 related articles for article (PubMed ID: 7518596)
1. Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management. Murray NP Biol Res; 2018 Sep; 51(1):32. PubMed ID: 30180883 [TBL] [Abstract][Full Text] [Related]
2. B4 androgen ablation: attacking the prostate cancer stem cell. Wicha MS J Clin Invest; 2013 Feb; 123(2):563-5. PubMed ID: 23348735 [TBL] [Abstract][Full Text] [Related]
3. Diagnosis of unknown nonhematological tumors by bone marrow biopsy: a retrospective analysis of 10,112 samples. Xiao L; Luxi S; Ying T; Yizhi L; Lingyun W; Quan P J Cancer Res Clin Oncol; 2009 May; 135(5):687-93. PubMed ID: 18956213 [TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease. Cote RJ; Rosen PP; Hakes TB; Sedira M; Bazinet M; Kinne DW; Old LJ; Osborne MP Am J Surg Pathol; 1988 May; 12(5):333-40. PubMed ID: 3364618 [TBL] [Abstract][Full Text] [Related]
6. Identification of bone marrow micrometastases in patients with prostate cancer. Wood DP; Banks ER; Humphreys S; McRoberts JW; Rangnekar VM Cancer; 1994 Nov; 74(9):2533-40. PubMed ID: 7522952 [TBL] [Abstract][Full Text] [Related]
7. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group]. Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478 [TBL] [Abstract][Full Text] [Related]
8. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Deguchi T; Yang M; Ehara H; Ito S; Nishino Y; Takahashi Y; Ito Y; Shimokawa K; Tanaka T; Imaeda T; Doi T; Kawada Y Br J Cancer; 1997; 75(5):634-8. PubMed ID: 9043017 [TBL] [Abstract][Full Text] [Related]
9. Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. Bretton PR; Melamed MR; Fair WR; Cote RJ Prostate; 1994 Aug; 25(2):108-14. PubMed ID: 7518596 [TBL] [Abstract][Full Text] [Related]
10. Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen. Moul JW; Lewis DJ; Ross AA; Kahn DG; Ho CK; McLeod DG Urology; 1994 Jan; 43(1):68-73. PubMed ID: 7506855 [TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. Oesterling JE J Urol; 1991 May; 145(5):907-23. PubMed ID: 1707989 [TBL] [Abstract][Full Text] [Related]
12. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. Gomella LG; Raj GV; Moreno JG J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297 [TBL] [Abstract][Full Text] [Related]